|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of 20 genes aberrantly methylated in human breast cancers.
|
15818620 |
2005 |
|
Breast Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of 20 genes aberrantly methylated in human breast cancers.
|
15818620 |
2005 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of 20 genes aberrantly methylated in human breast cancers.
|
15818620 |
2005 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of 20 genes aberrantly methylated in human breast cancers.
|
15818620 |
2005 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of 20 genes aberrantly methylated in human breast cancers.
|
15818620 |
2005 |
|
Smoking
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer.
|
26053186 |
2015 |
|
Smoking Behaviors
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer.
|
26053186 |
2015 |
|
Cervix carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.
|
31390052 |
2019 |
|
Cervix carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
Two hundred and sixty samples with available frozen cell pellets including 70 randomly selected cases of negative for intraepithelial lesion or malignancy (NILM)&HPV-negative, 70 randomly selected cases of NILM&HPV-positive, and 120 cytologic abnormalities & HPV-positive from a population-based cervical cancer screening program (n = 7,604) were investigated for the DNA methylation pattern of CADM1, FAM19A4, and MAL.
|
30608989 |
2019 |
|
Cervix carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
Within screening round capability of FAM19A4/mir124-2 methylation to detect cervical cancer was 100% (11/11, 95% CI: 71.5-100).
|
29663363 |
2018 |
|
Cervix carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
(3)There were no significant differences of FAM19A4 methylation in different clinicopathological parameters of cervical cancer.
|
30486875 |
2018 |
|
Cervix carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
Recently, DNA methylation analysis of FAM19A4 in cervical scrapes has been shown to adequately detect high-grade cervical intraepithelial neoplasia and cervical cancer (≥ CIN3) in high-risk HPV (hrHPV)-positive women.
|
26317579 |
2016 |
|
Cervix carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In conclusion, FAM19A4 is an attractive triage marker for hrHPV-positive women, with a high reassurance for the detection of cervical carcinoma and advanced CIN2/3 lesions.
|
25281488 |
2014 |
|
Malignant Neoplasms
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
The detection of cancer-associated host-cell DNA methylation (FAM19A4 and hsa-mir124-2) in cervical samples has shown valuable as triage test.
|
30758084 |
2019 |
|
Malignant tumor of cervix
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
Two hundred and sixty samples with available frozen cell pellets including 70 randomly selected cases of negative for intraepithelial lesion or malignancy (NILM)&HPV-negative, 70 randomly selected cases of NILM&HPV-positive, and 120 cytologic abnormalities & HPV-positive from a population-based cervical cancer screening program (n = 7,604) were investigated for the DNA methylation pattern of CADM1, FAM19A4, and MAL.
|
30608989 |
2019 |
|
Malignant tumor of cervix
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.
|
31390052 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
The detection of cancer-associated host-cell DNA methylation (FAM19A4 and hsa-mir124-2) in cervical samples has shown valuable as triage test.
|
30758084 |
2019 |
|
cervical cancer
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
Two hundred and sixty samples with available frozen cell pellets including 70 randomly selected cases of negative for intraepithelial lesion or malignancy (NILM)&HPV-negative, 70 randomly selected cases of NILM&HPV-positive, and 120 cytologic abnormalities & HPV-positive from a population-based cervical cancer screening program (n = 7,604) were investigated for the DNA methylation pattern of CADM1, FAM19A4, and MAL.
|
30608989 |
2019 |
|
cervical cancer
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.
|
31390052 |
2019 |
|
Malignant Neoplasms
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
However, in consideration of the limitations of this retrospective study, prospective population-based studies are necessary for further confirmation of the diagnostic value of FAM19A4 methylation for detection of cervical (pre)cancer in Chinese women.
|
30486875 |
2018 |
|
Malignant tumor of cervix
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
Within screening round capability of FAM19A4/mir124-2 methylation to detect cervical cancer was 100% (11/11, 95% CI: 71.5-100).
|
29663363 |
2018 |
|
Malignant tumor of cervix
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
(3)There were no significant differences of FAM19A4 methylation in different clinicopathological parameters of cervical cancer.
|
30486875 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
However, in consideration of the limitations of this retrospective study, prospective population-based studies are necessary for further confirmation of the diagnostic value of FAM19A4 methylation for detection of cervical (pre)cancer in Chinese women.
|
30486875 |
2018 |
|
cervical cancer
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
(3)There were no significant differences of FAM19A4 methylation in different clinicopathological parameters of cervical cancer.
|
30486875 |
2018 |
|
cervical cancer
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
Within screening round capability of FAM19A4/mir124-2 methylation to detect cervical cancer was 100% (11/11, 95% CI: 71.5-100).
|
29663363 |
2018 |